GSK 525762

Drug Profile

GSK 525762

Alternative Names: GSK525762

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Benzodiazepines; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Carcinoma; Haematological malignancies; Solid tumours
  • Phase I Prostate cancer

Most Recent Events

  • 31 May 2017 Phase-I clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Late-stage disease) in USA (PO) (NCT03150056)
  • 15 May 2017 GlaxoSmithKline plans a phase I trial for Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) (NCT03150056)
  • 01 Feb 2017 Phase-I/II clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02964507)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top